Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Sponsor: Alnylam Pharmaceuticals
Summary
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2025-12-12
Completion Date
2027-03-23
Last Updated
2026-03-31
Healthy Volunteers
Yes
Conditions
Interventions
ALN-4285
ALN-4285 will be administered SC
Placebo
Placebo will be administered SC
Locations (1)
Clinical Trial Site
London, United Kingdom